Prescription Stimulant Misuse Workplace Risks: 40+ Statistics 2025-26

VelSafe Insights

Prescription Stimulant Misuse and Workplace Risks: 40+ Statistics Through 2025-26

A landmark 2025 JAMA Psychiatry study found that 1 in 4 adults using prescription stimulants reported misuse, and nearly 1 in 10 met criteria for stimulant use disorder. In the workplace, amphetamine urine test positivity rose to 1.7% in 2024 – up from 1.5% in 2023 – and hair test positivity for amphetamines reached 2.3% in 2025, a 27.8% increase since 2021. Stimulant prescriptions increased 60% from 2012 to 2023. The DEA telemedicine waivers for controlled substance prescribing have been extended through the end of 2026. This article compiles 40+ statistics on prescription stimulant misuse, workplace drug testing, safety impacts, and the evolving regulatory landscape.

40+ Statistics

JAMA Psychiatry 2025

Quest Diagnostics DTI

2025-26 Regulatory Updates

25.3%

of U.S. adults using prescription stimulants reported misuse – 1 in 4 – per a landmark 2025 JAMA Psychiatry study by NIDA, SAMHSA, and CDC

JAMA Psychiatry, March 2025

60%

Increase in stimulant prescriptions dispensed from 2012 to 2023 – from 50.4 million to 80.8 million prescriptions per year

DEA-commissioned report / Contemporary Pediatrics

1.7%

Amphetamine urine test positivity in the U.S. general workforce in 2024 – second only to marijuana, up from 1.5% in 2023

Quest Diagnostics 2025 DTI (8M+ tests)

Prescription stimulants occupy a distinct and complicated position in the workplace substance use landscape. Unlike illicit drugs, they are legally prescribed, widely available, and often framed as productivity tools rather than substances of misuse. But the data from 2024 and 2025 tells a different story. One in four adults who are prescribed stimulants misuses them. Nearly one in ten meets criteria for prescription stimulant use disorder. Amphetamine positivity in workplace drug tests has risen consecutively for two years. And the stimulant shortage that began in 2022 has pushed some patients toward unregulated markets where counterfeit pills laced with fentanyl are an increasing risk.

The regulatory environment is also shifting. In January 2025, the DEA proposed a new framework for telemedicine prescribing of controlled substances. The telemedicine waivers that expanded stimulant access during the pandemic have been extended through the end of 2026. Stimulant prescriptions rose 60% from 2012 to 2023. Below we have compiled 40+ statistics on prescription stimulant misuse prevalence, workplace drug testing trends, safety impacts, the prescription shortage, and the current regulatory picture through 2025-26.

Editor's Choice: Key Prescription Stimulant Statistics for 2025-26

9.0%

of U.S. adults using prescription stimulants met criteria for prescription stimulant use disorder (PSUD), per the 2025 JAMA Psychiatry study by NIDA, SAMHSA, and CDC. (JAMA Psychiatry, March 2025)

3.1x

Higher misuse rate for amphetamine users compared to methylphenidate users. Amphetamine users were also 2.2x more likely to develop PSUD. (JAMA Psychiatry, 2025)

4.3M

Individuals aged 12 and older in the U.S. misused ADHD stimulants in 2022, the most recent year with published prevalence data at that population level. (Psychiatry Advisor, citing SAMHSA)

2.3%

Amphetamine hair test positivity in the general U.S. workforce in 2025 – up 27.8% from 1.8% in 2021. Hair tests capture 90-day use patterns and are more resistant to tampering. (Quest Diagnostics 2026 DTI, July 2026)

80.8M

Stimulant prescriptions dispensed in the U.S. in 2023 – up from 50.4 million in 2012, a 60% increase over 11 years driven by ADHD diagnoses, telehealth access, and adult treatment demand. (DEA-commissioned report)

78.2%

of prescription stimulant misusers surveyed reported performance enhancement – focus, productivity, or academic performance – as their primary motivation for illicit use. (AddictionHelp.com, citing survey data)

1. Prevalence of Prescription Stimulant Misuse: 2025 National Data

25.3%

Adults using Rx stimulants who report misuse

JAMA Psychiatry, 2025

9.0%

Meet criteria for prescription stimulant use disorder (PSUD)

JAMA Psychiatry, 2025

1.4%

Americans aged 12+ misused Rx stimulants in the prior year (2023 NSDUH data)

NSDUH 2023 / AHRQ

3.9M

People misused Rx stimulants in prior year (2023 estimate)

NSDUH 2023 / AHRQ

A March 2025 JAMA Psychiatry study by researchers from NIDA, SAMHSA, and CDC found that 25.3% of U.S. adults using prescription stimulants reported misuse – approximately 1 in 4 – and 9.0% met diagnostic criteria for prescription stimulant use disorder. (JAMA Psychiatry, 2025; MedicalXpress, March 2025)
Among those with PSUD, 72.9% used only their own prescribed stimulants – not diverted medications – and 87.1% were prescribed amphetamines. This underscores that misuse predominantly involves prescribed medications rather than diverted supply. (JAMA Psychiatry, 2025)
The 2023 National Survey on Drug Use and Health (NSDUH) found that an estimated 1.4% of Americans aged 12 and older – approximately 3.9 million people – misused prescription stimulants in the prior year. Past-month misuse prevalence was 0.4%. (NSDUH 2023; AHRQ Rapid Evidence Product, July 2025)
In 2022, more than 4.3 million individuals aged 12 and older misused ADHD stimulants – a figure that has declined from peak levels, likely reflecting the worldwide stimulant shortage, which suggests supply restriction may be an effective policy lever. (Psychiatry Advisor, citing SAMHSA 2022 data)
In 2020, the prevalence of stimulant misuse among all U.S. adults was 1.9% overall, including 1.6% for amphetamine-based medications, 0.3% for methylphenidate, and 0.2% for modafinil – figures that frame the population-level magnitude of the issue. (RADARS System / AHRQ, 2025)
Near 7% of U.S. adults used prescription stimulants in the past year in 2020, indicating that a substantial subset were using medications either without a prescription or in ways not prescribed. (Psychology Today, April 2025, citing national data)

2. Who Is Misusing Prescription Stimulants: Demographics and Patterns

Young Adults (Highest Misuse)

Misuse rates are highest among younger adults. From 2019 to 2023, nonmedical use among 12th graders fell from 2.5% to 1.6% – but diversion studies still find 21.7% reporting diversion in college settings.

Women Aged 35-64 (Fastest Growing)

Prescriptions dispensed to women aged 35-64 rose from 1.2 million in early 2019 to 1.7 million by late 2022. Their misuse rate (13.7%) is lower than younger adults but the prescription growth signals expanding risk.

Amphetamine vs. Methylphenidate

Amphetamine users are 3.1x more likely to misuse and 2.2x more likely to develop PSUD than methylphenidate users. 87.1% of those with PSUD are prescribed amphetamines – making amphetamine products the dominant risk vector.

Prescriptions for stimulants increased across all demographics in 2025 JAMA data, with the most substantial rise occurring among women aged 35 to 64 – growing from 1.2 million in early 2019 to 1.7 million by late 2022 – while their misuse rate of 13.7% was lower than younger adults. (JAMA Psychiatry, 2025)
Amphetamine users were 3.1 times more likely to misuse their medication than those prescribed methylphenidate, and had a 2.2 times greater likelihood of developing PSUD – a finding with direct implications for risk stratification in workplace health programs. (JAMA Psychiatry, 2025)
From 2019 to 2023, nonmedical use of prescription stimulants among 12th graders fell from 2.5% to 1.6%, yet diversion-focused studies still find 21.7% of college students reporting diversion and 29.7% reporting misuse, sale, or diversion activity. (Gitnux / NSDUH; ADHD statistics review)
78.2% of prescription stimulant misusers report that their primary motivation is performance enhancement – focus, productivity, or academic performance – rather than recreational intoxication, which shapes both the risk profile and the detection challenge in professional work environments. (AddictionHelp.com, citing survey data)
Approximately 15.5 million adults and 7 million children in the United States have an ADHD diagnosis, creating a large population of prescription-holders whose medication may be misused by themselves or diverted to others. (ADHD Advisor / Psychology Today, 2025)

3. Stimulant Prescription Growth, the ADHD Shortage, and the Telemedicine Connection

Stimulant Prescription Volume Growth Timeline

2006-2016

Stimulant prescriptions surged 250%, while ADHD diagnoses increased only minimally – the first major divergence between diagnostic rates and prescribing volume.

2012-2023

Total stimulant prescriptions dispensed grew from 50.4 million to 80.8 million annually – a 60% increase. Prescriptions up 14% from 2020 to 2022 alone, driven substantially by telemedicine expansion during and after COVID-19.

Oct 2022

FDA announced Adderall shortage. DEA production quotas, manufacturing supply chain issues, and surging demand combined to produce a billion-dose shortfall in both 2022 and 2023.

Jan 2025

DEA proposed new regulations for telemedicine prescribing of controlled substances, aiming to balance access with prevention of misuse – a framework still being finalized as of mid-2026.

Through 2026

DEA telemedicine waivers for controlled substance prescribing (including ADHD stimulants) extended through the end of 2026, maintaining expanded prescribing access without in-person evaluation requirements.

Sources: Psychology Today (2025); Contemporary Pediatrics (2026); DEA; MedVidi (2026)

The number of stimulant prescriptions dispensed in the U.S. increased 60% from 2012 to 2023 – from 50.4 million to 80.8 million annually – driven by expanded adult ADHD recognition, telemedicine access, and prescribing during the COVID-19 pandemic. (DEA-commissioned report, cited in Contemporary Pediatrics, 2026)
Stimulant prescriptions increased by 14% from 2020 to 2022 alone, especially among young adults, and the percentage of individuals with stimulant prescriptions at pharmacies rose from 3.6% in 2016 to 4.1% in 2021. (Psychology Today, April 2025)
From August 2019 to August 2020, telemedicine insurance claims increased by 3,552%. This expansion coincided with the COVID-era suspension of the Ryan Haight Act, which had previously required in-person evaluation before prescribing controlled substances including ADHD medications. (Rittenhouse Psychiatric Associates, citing HHS data)
The ADHD stimulant shortage, which began in October 2022, produced a billion-dose shortfall in both 2022 and 2023 – below DEA-allowed production limits – affecting legitimate ADHD patients while pushing some toward unregulated markets where counterfeit pills laced with fentanyl pose a serious risk. (ADHD Treatment 2025 / AllMedRx, January 2026)
In January 2025, the DEA proposed a new regulatory framework for telemedicine prescribing of controlled substances, aiming to create structured pathways that balance treatment access with prevention of diversion and misuse – without the blanket waivers granted during the pandemic. (Psychology Today, April 2025)
The DEA telemedicine waivers for controlled substance prescribing – which allow stimulant prescriptions without in-person evaluation – have been extended through the end of 2026, maintaining the expanded access environment that contributed to prescription volume growth. (MedVidi, March 2026)

4. Stimulants in Workplace Drug Testing: Amphetamine Positivity Data 2023-2025

Urine test positivity 2023

1.5% (general workforce)

Urine test positivity 2024

1.7% (+13.3% YoY)

Oral fluid positivity 2024

1.2% (recent-use window)

Hair test positivity 2025

2.3% (+27.8% since 2021)

DOT mandated urine 2024

0.80% (second to marijuana)

Sources: Quest Diagnostics 2025 DTI (2024 data); Quest 2026 DTI (2025 data)

Amphetamine urine test positivity in the general U.S. workforce rose to 1.7% in 2024, up from 1.5% in 2023 – a consecutive year-over-year increase that makes amphetamines the second most commonly detected drug category in workplace urine testing, behind only marijuana at 4.5%. (Quest Diagnostics 2025 DTI; EHSLeaders, December 2025)
Oral fluid tests for amphetamines in 2024 showed 1.2% positivity, capturing more recent use patterns than urine testing and reflecting likely workplace exposure within hours to days rather than weeks. (Quest Diagnostics 2025 DTI)
Hair test positivity for amphetamines in the general workforce reached 2.3% in 2025, up 27.8% from 1.8% in 2021 – a four-year trend of rising amphetamine detection in the test method that captures the longest use history. (Quest Diagnostics 2026 DTI, July 2026; PR Newswire)
In federally mandated (DOT-regulated) tests, amphetamines were the second most detected drug at 0.80% in 2024, just below marijuana at 0.87% – and ahead of all other drug categories in the safety-sensitive transportation workforce. (Quest Diagnostics 2025 DTI)
The healthcare sector recorded the highest overall drug positivity rate at 5.8% in 2025 (up from 5.1% in 2021), with the increase largely attributed to marijuana and amphetamines – meaning the sector with the most vulnerable patient population also has the highest stimulant-related positivity trends. (Quest Diagnostics 2026 DTI / CLPMag, July 2026)
Amphetamine co-positivity with fentanyl in workforce drug tests rose from 11% in 2020 to 16% in 2024 – meaning an increasing proportion of workers positive for fentanyl are also positive for amphetamines, creating a polysubstance impairment risk more severe than either drug alone. (Quest Diagnostics 2025 DTI)

5. Workplace Safety Impact: Accidents, Impairment, and Performance Effects

Cognitive and Physical Impairment

Stimulant impairment leads to poor judgment, decreased reaction times, mood swings, and higher accident risk. These effects are especially dangerous in construction, transportation, and manufacturing where lapses have catastrophic consequences.

Inconsistent Performance

Workers abusing prescription stimulants often show inconsistent work quality, missed deadlines, and increased errors – followed by crash periods of fatigue and reduced cognitive capacity when the drug’s effects wear off.

Psychosis and Cardiovascular Risk

A 2024 American Journal of Psychiatry study found increased risk of incident psychosis and mania with prescription amphetamines – a risk beyond accident impairment that affects workplace behavior and mental health stability.

Stimulant impairment in the workplace causes poor judgment, decreased reaction times, mood swings, and a significantly higher risk of accidents – with risks especially severe in safety-sensitive roles such as construction, transportation, and manufacturing. (WorkSafeBC, 2024)
A 2024 study published in the American Journal of Psychiatry found increased risk of incident psychosis and mania with prescription amphetamine use – a safety consequence beyond physical impairment, affecting workplace behavior, interpersonal stability, and decision-making. (AJP, October 2024; NCBI, 2025)
Approximately 23% of the U.S. workforce has used prescription drugs non-medically, with consequences including absenteeism, impaired performance, and accidents that directly affect organizational efficiency and productivity. (National Drug and Alcoholism data, cited in original study)
Workers misusing stimulants typically begin with a perceived productivity benefit – focus and alertness – but the performance profile is not linear. Crash periods of fatigue, irritability, and cognitive impairment follow stimulant cycles and may be more dangerous than the stimulant-active periods in settings requiring sustained concentration. (Harmony Ridge Recovery, 2024; WorkSafeBC)
Emergency department visits related to non-medical use of prescription stimulants among adults grew from 5,212 in 2005 to 15,585 in 2010 – a near-tripling in five years – establishing the trend that more recent data continues to reflect. (Drug Abuse Warning Network, cited in AHRQ Rapid Evidence Product, 2025)
In Rhode Island overdose deaths involving polysubstance use from 2017 to 2020, prescription amphetamines or methylphenidate contributed to 39 accidental deaths, with 90% also involving opioids – confirming the polysubstance mortality risk that workplace testing data is increasingly capturing. (Psychiatry Advisor, citing study data)

6. Employer Concern and Policy Landscape for Prescription Stimulant Misuse

67%

of U.S. employers concerned about prescription drug misuse in workforce

NSC Employer Survey, 2018

States with operational prescription drug monitoring programs (PDMPs) as of 2024

NASPMP 2024

5.8%

Overall drug positivity in healthcare sector in 2025 – highest of any industry, driven by amphetamines and marijuana

Quest Diagnostics 2026 DTI

A National Safety Council survey found that 67% of U.S. employers were concerned about prescription drug misuse in their workforce, viewing it as equally or more impactful than workplace violence and more concerning than illegal drug use. (NSC Employer Survey, 2018 – the most recent published employer-level survey data)
49 of 50 U.S. states had operational Prescription Drug Monitoring Programs (PDMPs) as of 2024 – a near-national infrastructure for tracking controlled substance prescribing that states increasingly integrate with occupational health and employer drug programs. (NASPMP, 2024 status update)
The healthcare sector’s 5.8% overall drug positivity rate in 2025 – driven partly by amphetamines – represents a particularly acute employer concern, as healthcare workers in patient-care roles operate in safety-sensitive environments where impairment from any substance creates direct patient risk. (Quest Diagnostics 2026 DTI / CLPMag, July 2026)
The challenge for employers is that no validated test currently exists for real-time stimulant impairment. Unlike blood alcohol content testing, positive amphetamine drug test results confirm use but cannot precisely confirm impairment at the time of testing – creating policy complexity particularly when an employee holds a legitimate prescription. (WorkSafeBC, 2024; industry consensus)
Employer drug-free workplace programs that include prescription stimulants should address both declared and undeclared use – requiring employees in safety-sensitive roles to disclose prescription stimulant use to occupational health, similar to requirements for other prescribed medications that affect fitness for duty. (industry best practice; NSC)

7. Regulatory Landscape in 2025-26: DEA, FDA, and Telemedicine Policy Updates

FDA Rapid Review (2024)

In 2024, the FDA requested a rapid review of ADHD stimulant misuse among adults, resulting in the AHRQ report published July 2025 covering 2004-2024 literature. The three FDA key questions addressed patterns, trends, and consequences.

DEA Telemedicine Framework (Jan 2025)

DEA proposed new regulations in January 2025 to establish a framework for telemedicine prescribing of controlled substances, aiming to create structured pathways with appropriate safeguards against diversion – replacing pandemic-era blanket waivers.

Telemedicine Waivers Extended (2026)

DEA telemedicine waivers allowing controlled substance prescribing without in-person evaluation have been extended through the end of 2026. This maintains the expanded prescribing environment for ADHD medications while the new framework is finalized.

DOJ Enforcement (June 2024)

On June 13, 2024, the DOJ charged two individuals behind Done Global Inc. with health care fraud for facilitating Adderall access without justification – the most prominent telemedicine stimulant diversion enforcement action to date.

In 2024, the FDA requested a rapid review of ADHD stimulant misuse among adults, marking the most significant federal acknowledgment of the scope of the problem since SAMHSA’s NSDUH data began capturing stimulant-specific misuse rates. (Psychiatry Advisor, June 2026)
The resulting AHRQ Rapid Evidence Product, published July 2025, covered published research from 2004 through September 2024 and identified persistent misuse patterns, demographic trends, and evidence gaps – including the finding that the stimulant shortage itself appeared to reduce misuse rates. (AHRQ, July 2025)
The January 2025 DEA telemedicine proposal addresses the post-pandemic structural change: from August 2019 to August 2020, telemedicine insurance claims increased 3,552%, and prescribing of controlled substances through online platforms contributed substantially to the stimulant shortage. (Psychology Today, April 2025)
The June 2024 DOJ enforcement action against Done Global charged the founders of a telemedicine ADHD platform with health care fraud for facilitating stimulant access without appropriate clinical justification – the highest-profile diversion enforcement in the telehealth stimulant space. (Contemporary Pediatrics, 2026)
With DEA production quota increases approved in September 2024 for some ADHD medications and telemedicine waivers extended through 2026, the stimulant shortage – while not fully resolved – is expected to ease further into late 2025 and 2026, potentially increasing prescription access and associated misuse risk. (ADHD Advisor, 2026)

Key Takeaways for Safety Managers and HR Professionals

1 in 4 stimulant users misuses – this is not a fringe issue

A 25.3% misuse rate among prescription stimulant users means this is a mainstream compliance and safety consideration for any organization where employees hold these prescriptions. Given that 80.8 million stimulant prescriptions were dispensed in 2023, the workforce exposure is significant.

Amphetamine positivity is rising – year over year

Urine test amphetamine positivity rose from 1.5% (2023) to 1.7% (2024), and hair test positivity climbed 27.8% between 2021 and 2025. These are consistent upward trends, not random variation. Organizations that review drug testing data annually should be treating amphetamine positivity as a tracked metric.

Healthcare is the highest-risk sector

Healthcare workers recorded the highest overall drug positivity rate (5.8% in 2025), driven in part by amphetamines. This is the sector with the least tolerance for impairment and the most direct patient harm risk. Safety managers in healthcare should treat stimulant misuse as a priority intervention area.

Amphetamine type matters – prescriptions do not all carry equal risk

Amphetamine users are 3.1x more likely to misuse than methylphenidate users. Occupational health programs that require medication disclosure from employees in safety-sensitive roles should understand this risk differential when conducting fitness-for-duty assessments.

Polysubstance risk is increasing

Amphetamine co-positivity with fentanyl rose from 11% to 16% between 2020 and 2024. Workers testing positive for fentanyl are increasingly also testing positive for amphetamines – a combination with extreme impairment and overdose risk. Post-accident testing should explicitly examine polysubstance results, not single-drug findings.

Telemedicine access creates new prescribing and diversion pathways

With telemedicine waivers for controlled substances extended through 2026, stimulant access via online platforms remains easier than at any point before 2020. Employees who would not have received prescriptions without in-person evaluation can now access them online. Fitness-for-duty disclosure policies need to account for this prescribing landscape shift.

Sources

Government and Research Sources

Industry and Research Sources